Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Identifieur interne : 000A92 ( Main/Exploration ); précédent : 000A91; suivant : 000A93Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Auteurs : Ebrahim Variava [États-Unis] ; Farai R. Sigauke ; Jennifer Norman ; Modiehi Rakgokong ; Petudzai Muchichwa ; Andre Mochan ; Gary Maartens ; Neil A. MartinsonSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Agents antiVIH (administration et posologie), Agents antiVIH (effets indésirables), Agents antiVIH (pharmacocinétique), Association de médicaments, Ataxie (), Benzoxazines (administration et posologie), Benzoxazines (effets indésirables), Benzoxazines (pharmacocinétique), Calendrier d'administration des médicaments, Charge virale, Encéphalopathies (), Femelle, Humains, Infections à VIH (mortalité), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Jeune adulte, Lamivudine (administration et posologie), Lamivudine (pharmacocinétique), Numération des lymphocytes CD4, Relation dose-effet des médicaments, République d'Afrique du Sud, Résultat thérapeutique, Ténofovir (administration et posologie), Ténofovir (pharmacocinétique).
- MESH :
- administration et posologie : Agents antiVIH, Benzoxazines, Lamivudine, Ténofovir.
- effets indésirables : Agents antiVIH, Benzoxazines.
- mortalité : Infections à VIH.
- pharmacocinétique : Agents antiVIH, Benzoxazines, Lamivudine, Ténofovir.
- traitement médicamenteux : Infections à VIH.
- virologie : Infections à VIH.
- Adulte, Association de médicaments, Ataxie, Calendrier d'administration des médicaments, Charge virale, Encéphalopathies, Femelle, Humains, Jeune adulte, Numération des lymphocytes CD4, Relation dose-effet des médicaments, République d'Afrique du Sud, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Anti-HIV Agents (pharmacokinetics), Ataxia (chemically induced), Benzoxazines (administration & dosage), Benzoxazines (adverse effects), Benzoxazines (pharmacokinetics), Brain Diseases (chemically induced), CD4 Lymphocyte Count, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections (drug therapy), HIV Infections (mortality), HIV Infections (virology), Humans, Lamivudine (administration & dosage), Lamivudine (pharmacokinetics), South Africa, Tenofovir (administration & dosage), Tenofovir (pharmacokinetics), Treatment Outcome, Viral Load, Young Adult.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Benzoxazines, Lamivudine, Tenofovir.
- chemical , adverse effects : Anti-HIV Agents, Benzoxazines.
- chemical , pharmacokinetics : Anti-HIV Agents, Benzoxazines, Lamivudine, Tenofovir.
- chemically induced : Ataxia, Brain Diseases.
- drug therapy : HIV Infections.
- mortality : HIV Infections.
- virology : HIV Infections.
- Adult, CD4 Lymphocyte Count, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, South Africa, Treatment Outcome, Viral Load, Young Adult.
Abstract
WHO treatment guidelines recommend efavirenz in first-line antiretroviral therapy (ART). Efavirenz commonly causes early transient neuropsychiatric adverse events. We present 20 cases with severe encephalopathy accompanied by ataxia due to efavirenz toxicity.
DOI: 10.1097/QAI.0000000000001451
PubMed: 28520619
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D50
- to stream PubMed, to step Curation: 000D50
- to stream PubMed, to step Checkpoint: 000D50
- to stream Ncbi, to step Merge: 004184
- to stream Ncbi, to step Curation: 004184
- to stream Ncbi, to step Checkpoint: 004184
- to stream Main, to step Merge: 000A92
- to stream Main, to step Curation: 000A92
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.</title><author><name sortKey="Variava, Ebrahim" sort="Variava, Ebrahim" uniqKey="Variava E" first="Ebrahim" last="Variava">Ebrahim Variava</name><affiliation wicri:level="2"><nlm:affiliation>*North West Department of Health, Klerksdorp Tshepong Hospital Complex, Matlosana, South Africa; †Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa; ‡Perinatal HIV Research Unit (PHRU), SA MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa; §Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; ‖Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa; and ¶Center for TB Research, Johns Hopkins University, Baltimore, MD.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>*North West Department of Health, Klerksdorp Tshepong Hospital Complex, Matlosana, South Africa; †Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa; ‡Perinatal HIV Research Unit (PHRU), SA MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa; §Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; ‖Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa; and ¶Center for TB Research, Johns Hopkins University, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Sigauke, Farai R" sort="Sigauke, Farai R" uniqKey="Sigauke F" first="Farai R" last="Sigauke">Farai R. Sigauke</name></author><author><name sortKey="Norman, Jennifer" sort="Norman, Jennifer" uniqKey="Norman J" first="Jennifer" last="Norman">Jennifer Norman</name></author><author><name sortKey="Rakgokong, Modiehi" sort="Rakgokong, Modiehi" uniqKey="Rakgokong M" first="Modiehi" last="Rakgokong">Modiehi Rakgokong</name></author><author><name sortKey="Muchichwa, Petudzai" sort="Muchichwa, Petudzai" uniqKey="Muchichwa P" first="Petudzai" last="Muchichwa">Petudzai Muchichwa</name></author><author><name sortKey="Mochan, Andre" sort="Mochan, Andre" uniqKey="Mochan A" first="Andre" last="Mochan">Andre Mochan</name></author><author><name sortKey="Maartens, Gary" sort="Maartens, Gary" uniqKey="Maartens G" first="Gary" last="Maartens">Gary Maartens</name></author><author><name sortKey="Martinson, Neil A" sort="Martinson, Neil A" uniqKey="Martinson N" first="Neil A" last="Martinson">Neil A. Martinson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28520619</idno><idno type="pmid">28520619</idno><idno type="doi">10.1097/QAI.0000000000001451</idno><idno type="wicri:Area/PubMed/Corpus">000D50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D50</idno><idno type="wicri:Area/PubMed/Curation">000D50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D50</idno><idno type="wicri:Area/PubMed/Checkpoint">000D50</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D50</idno><idno type="wicri:Area/Ncbi/Merge">004184</idno><idno type="wicri:Area/Ncbi/Curation">004184</idno><idno type="wicri:Area/Ncbi/Checkpoint">004184</idno><idno type="wicri:Area/Main/Merge">000A92</idno><idno type="wicri:Area/Main/Curation">000A92</idno><idno type="wicri:Area/Main/Exploration">000A92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.</title><author><name sortKey="Variava, Ebrahim" sort="Variava, Ebrahim" uniqKey="Variava E" first="Ebrahim" last="Variava">Ebrahim Variava</name><affiliation wicri:level="2"><nlm:affiliation>*North West Department of Health, Klerksdorp Tshepong Hospital Complex, Matlosana, South Africa; †Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa; ‡Perinatal HIV Research Unit (PHRU), SA MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa; §Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; ‖Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa; and ¶Center for TB Research, Johns Hopkins University, Baltimore, MD.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>*North West Department of Health, Klerksdorp Tshepong Hospital Complex, Matlosana, South Africa; †Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa; ‡Perinatal HIV Research Unit (PHRU), SA MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa; §Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; ‖Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa; and ¶Center for TB Research, Johns Hopkins University, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Sigauke, Farai R" sort="Sigauke, Farai R" uniqKey="Sigauke F" first="Farai R" last="Sigauke">Farai R. Sigauke</name></author><author><name sortKey="Norman, Jennifer" sort="Norman, Jennifer" uniqKey="Norman J" first="Jennifer" last="Norman">Jennifer Norman</name></author><author><name sortKey="Rakgokong, Modiehi" sort="Rakgokong, Modiehi" uniqKey="Rakgokong M" first="Modiehi" last="Rakgokong">Modiehi Rakgokong</name></author><author><name sortKey="Muchichwa, Petudzai" sort="Muchichwa, Petudzai" uniqKey="Muchichwa P" first="Petudzai" last="Muchichwa">Petudzai Muchichwa</name></author><author><name sortKey="Mochan, Andre" sort="Mochan, Andre" uniqKey="Mochan A" first="Andre" last="Mochan">Andre Mochan</name></author><author><name sortKey="Maartens, Gary" sort="Maartens, Gary" uniqKey="Maartens G" first="Gary" last="Maartens">Gary Maartens</name></author><author><name sortKey="Martinson, Neil A" sort="Martinson, Neil A" uniqKey="Martinson N" first="Neil A" last="Martinson">Neil A. Martinson</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (adverse effects)</term><term>Anti-HIV Agents (pharmacokinetics)</term><term>Ataxia (chemically induced)</term><term>Benzoxazines (administration & dosage)</term><term>Benzoxazines (adverse effects)</term><term>Benzoxazines (pharmacokinetics)</term><term>Brain Diseases (chemically induced)</term><term>CD4 Lymphocyte Count</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (mortality)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Lamivudine (administration & dosage)</term><term>Lamivudine (pharmacokinetics)</term><term>South Africa</term><term>Tenofovir (administration & dosage)</term><term>Tenofovir (pharmacokinetics)</term><term>Treatment Outcome</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (effets indésirables)</term><term>Agents antiVIH (pharmacocinétique)</term><term>Association de médicaments</term><term>Ataxie ()</term><term>Benzoxazines (administration et posologie)</term><term>Benzoxazines (effets indésirables)</term><term>Benzoxazines (pharmacocinétique)</term><term>Calendrier d'administration des médicaments</term><term>Charge virale</term><term>Encéphalopathies ()</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (mortalité)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Jeune adulte</term><term>Lamivudine (administration et posologie)</term><term>Lamivudine (pharmacocinétique)</term><term>Numération des lymphocytes CD4</term><term>Relation dose-effet des médicaments</term><term>République d'Afrique du Sud</term><term>Résultat thérapeutique</term><term>Ténofovir (administration et posologie)</term><term>Ténofovir (pharmacocinétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term><term>Lamivudine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term><term>Lamivudine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Benzoxazines</term><term>Lamivudine</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Ataxia</term><term>Brain Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Benzoxazines</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Agents antiVIH</term><term>Benzoxazines</term><term>Lamivudine</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>South Africa</term><term>Treatment Outcome</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Association de médicaments</term><term>Ataxie</term><term>Calendrier d'administration des médicaments</term><term>Charge virale</term><term>Encéphalopathies</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Numération des lymphocytes CD4</term><term>Relation dose-effet des médicaments</term><term>République d'Afrique du Sud</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">WHO treatment guidelines recommend efavirenz in first-line antiretroviral therapy (ART). Efavirenz commonly causes early transient neuropsychiatric adverse events. We present 20 cases with severe encephalopathy accompanied by ataxia due to efavirenz toxicity.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Maartens, Gary" sort="Maartens, Gary" uniqKey="Maartens G" first="Gary" last="Maartens">Gary Maartens</name><name sortKey="Martinson, Neil A" sort="Martinson, Neil A" uniqKey="Martinson N" first="Neil A" last="Martinson">Neil A. Martinson</name><name sortKey="Mochan, Andre" sort="Mochan, Andre" uniqKey="Mochan A" first="Andre" last="Mochan">Andre Mochan</name><name sortKey="Muchichwa, Petudzai" sort="Muchichwa, Petudzai" uniqKey="Muchichwa P" first="Petudzai" last="Muchichwa">Petudzai Muchichwa</name><name sortKey="Norman, Jennifer" sort="Norman, Jennifer" uniqKey="Norman J" first="Jennifer" last="Norman">Jennifer Norman</name><name sortKey="Rakgokong, Modiehi" sort="Rakgokong, Modiehi" uniqKey="Rakgokong M" first="Modiehi" last="Rakgokong">Modiehi Rakgokong</name><name sortKey="Sigauke, Farai R" sort="Sigauke, Farai R" uniqKey="Sigauke F" first="Farai R" last="Sigauke">Farai R. Sigauke</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Variava, Ebrahim" sort="Variava, Ebrahim" uniqKey="Variava E" first="Ebrahim" last="Variava">Ebrahim Variava</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28520619
|texte= Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28520619" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |